LexDanaLexDanabeta
Inventor

Wayne A. Marasco

Inventor
Wellesley, MA, US

Overview

44→
Patents
1998–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 44 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary
C07KPeptides29%
A61KPreparations for medical, dental or toiletry purposes26%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
C12NMicroorganisms or enzymes12%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
C40BCombinatorial chemistry2%
Y02ATechnologies for adaptation to climate change2%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms1%
C12YEnzymes1%
PatentTitleYear
11,104,722Immunogenetic restriction on elicitation of antibodies202111,046,777Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof202110,899,825Flavivirus neutralizing antibodies and methods of use thereof202110,870,694Composition and methods of treating B cell disorders202010,870,705Chimeric antigen receptors specific for carbonic acid anhydrase IX202010,851,155Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof202010,774,134Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use202010,675,349Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof202010,604,581Human monoclonal anti-PD-L1 antibodies and methods of use202010,584,172Humanized monoclonal antibodies and methods of use202010,556,956Pharmaceutical compositions comprising humanized anti-CCR4 IgG4 antibody202010,463,732Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof201910,450,383Carbonic anhydrase IX (G250) antibodies and methods of use thereof201910,400,032Flavivirus neutralizing antibodies and methods of use thereof201910,179,822Humanized monoclonal antibodies and methods of use201910,131,704Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof20189,951,122Antibodies against influenza virus and methods of use thereof20189,828,434Human monoclonal anti-PD-L1 antibodies and methods of use20179,822,166'Flavivirus neutralizing antibodies and methods of use thereof'20179,676,867'Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibody'20179,587,028'Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use'20179,527,924'Humanized monoclonal antibodies and methods of use'20169,441,045'Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use'20169,416,169'Humanized monoclonal antibodies and methods of use'20168,962,806'Humanized monoclonal antibodies and methods of use'20158,828,727'Lentiviral vectors and uses thereof'20148,466,263'Carbonic anhydrase IX (G250) anitbodies'20138,329,178'Antibodies against CXCR4 and methods of use thereof'20128,198,411'Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer'20127,786,269'Antibody to latent membrane proteins and uses thereof'20107,781,568'Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer'20107,750,123'Antibodies against SARS-CoV and methods of use thereof'20107,262,049'Pseudotyped lentiviral vectors and uses thereof'20077,186,697'Nucleic acid delivery system, methods of synthesis and use thereof'20077,078,031'Pseudotyped lentiviral vectors and uses thereof'20066,830,892'Lentiviral vector system for high quantity screening'20046,479,284'Humanized antibody and uses thereof'20026,329,173'Method of intracellular binding target molecules'20016,143,520'Expression vectors and methods of use'20006,072,036'Method of intracellular binding of target molecules'20006,004,940'Intracellular targeting of endogenous proteins'19995,965,371'Method of intracellular binding of target molecules'19995,852,186'Reactive neutralizing human anti-GP120 recombinant antibody, DNA coding the same and use thereof'19985,851,829'Method of intracellular binding of target molecules'1998

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1998–2021Patents assigned to DANA FARBER CANCER INST INC (42)· patent assignee history
1998–2021Based in Wellesley, MA, US· patent location history
2012–2016Patents assigned to MARASCO WAYNE A (4)· patent assignee history
2012–2016Patents assigned to SUI JIANHUA (3)· patent assignee history
2015–2017Patents assigned to BRIGHAM & WOMENS HOSPITAL (2)· patent assignee history
2018–2020Patents assigned to BURNHAM INSTITUTE FOR MEDICAL RES (2)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
DANA FARBER CANCER INST INC421998–2021
MARASCO WAYNE Aself42012–2016
SUI JIANHUA32012–2016
BRIGHAM & WOMENS HOSPITAL22015–2017
BURNHAM INSTITUTE FOR MEDICAL RES22018–2020
Locations
LocationPatentsSpan
Wellesley, Massachusetts, US441998–2021